Unknown

Dataset Information

0

Bioluminescence Imaging-Based Assessment of the Anti-Triple-Negative Breast Cancer and NF-Kappa B Pathway Inhibition Activity of Britanin.


ABSTRACT: Britanin has been reported to have therapeutic effects on neurodegenerative and inflammation-based diseases. However, whether it is involved in the regulation of triple-negative breast cancer development has not been elucidated. In this study, we investigated the anti-tumor activity against triple-negative breast cancer tumor of Britanin by bioluminescence imaging in vivo using athymic (nu/nu) mice implanted with MDA-MB-231 and SUM-159 cells expressing a luciferase reporter gene, and explored the anti-tumor mechanism of Britanin. The results showed that Britanin treatment inhibited triple-negative breast cancer cell proliferation in vivo, and Cell Counting Kit-8 (IC50 values are 4.27 and 5.05 ?M) and colony formation tests (P < 0.001) confirmed this result. Transwell assays were conducted to verify that Britanin treatment inhibited cell migration and invasion (P < 0.001). Apoptosis was determined by TdT-mediated dUTP nick-end labeling method. Western blot and qRT-PCR analysis showed that Britanin treatment caused a decrease in the member expression of NF-kappa B signaling pathway. Computational modeling showed that Britanin could directly bind to a p-65 core region composed of Cys38, Cys120, and Gln128 residues. The results showed that the inhibitory mechanisms of Britanin on cancer cells may be by ways of inhibiting the NF-kappa B pathway. In addition, bioluminescence imaging screening system is useful for accelerating the application of Britanin in the antitumor field, and provides a useful tool for evaluating the phytochemicals efficacy in inhibiting cancer cell proliferation in animal models.

SUBMITTER: Xu X 

PROVIDER: S-EPMC7215071 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Bioluminescence Imaging-Based Assessment of the Anti-Triple-Negative Breast Cancer and NF-Kappa B Pathway Inhibition Activity of Britanin.

Xu Xinyi X   Guo Yingying Y   Du Getao G   Liu Huifang H   Wang Lin L   Chen Dan D  

Frontiers in pharmacology 20200505


Britanin has been reported to have therapeutic effects on neurodegenerative and inflammation-based diseases. However, whether it is involved in the regulation of triple-negative breast cancer development has not been elucidated. In this study, we investigated the anti-tumor activity against triple-negative breast cancer tumor of Britanin by bioluminescence imaging <i>in vivo</i> using athymic (nu/nu) mice implanted with MDA-MB-231 and SUM-159 cells expressing a luciferase reporter gene, and expl  ...[more]

Similar Datasets

| S-EPMC7317048 | biostudies-literature
| S-EPMC7648025 | biostudies-literature
| S-EPMC3696905 | biostudies-other
| S-EPMC7160338 | biostudies-literature
| S-EPMC4015735 | biostudies-literature
| S-EPMC8699375 | biostudies-literature
| S-EPMC9368383 | biostudies-literature
| S-EPMC5612679 | biostudies-literature
| S-EPMC6217067 | biostudies-literature
| S-EPMC6557212 | biostudies-literature